The purpose of the study is to assess how effective and safe sonelokimab is for adults with moderate to severe hidradenitis suppurativa. Participants in the study will receive either sonelokimab or a placebo over a period of 16 weeks. During this time, researchers will monitor the participants to see if there is a 75% improvement in their condition, which is measured by a specific score called the Hidradenitis Suppurativa Clinical Response (HiSCR) score. The study will also track any side effects or adverse events that occur during the treatment period.

Throughout the study, participants will undergo regular check-ups, including physical examinations and laboratory tests, to ensure their safety and to gather data on the treatment’s effects. The trial aims to provide valuable information on whether sonelokimab can be a beneficial treatment option for those suffering from hidradenitis suppurativa, potentially improving their quality of life by reducing the severity of their symptoms.

Table of Contents

• Trial overview
• Who can join the study
• What is being measured
• Study design and comparison treatment
• Trial status and size

Trial overview

This study is an interventional trial, which means researchers give a study treatment and then watch what happens over time.^[1] It is testing NAV-240 in adults with moderate-to-severe hidradenitis suppurativa, a long-term skin condition that causes painful lumps and can lead to abscesses and draining tunnels.^[1]

The trial is in Phase 2, a stage that usually looks at whether a treatment seems to work and continues to collect safety information.^[1] The study title says it is designed to assess NAV-240 in adult participants with hidradenitis suppurativa.^[1]

Who can join the study

The available trial data says the study is for adult participants with moderate-to-severe hidradenitis suppurativa.^[1] No other eligibility details are provided in the source data, so the full entry criteria are not listed here.^[1]

What is being measured

The main endpoint is HiSCR 75 at Week 16, which stands for Hidradenitis Suppurativa Clinical Response 75.^[1] In simple terms, this means the study checks whether a participant has at least a 75% drop in inflamed skin bumps, called abscesses and inflammatory nodules, compared with the start of the study.^[1]

To count as a response, there must also be no increase in the number of abscesses or draining tunnels, which are channels under the skin that can leak fluid or pus.^[1] The study uses the start of treatment, called baseline, as the comparison point.^[1]

Study design and comparison treatment

The brief summary says the main goal is to find out whether NAV-240 works more effectively than a placebo, also called a dummy treatment.^[1] A placebo looks like a treatment but does not contain the study drug, so researchers can compare results fairly.^[1]

The intervention list includes NAV-240 and a sodium chloride solution used as the control treatment in the study record.^[1] Both are listed as being given by intravenous use, which means through a vein.^[1]

Trial status and size

The trial status is Authorised, meaning it has been approved to move forward in the source record.^[1] The planned enrollment is 204 participants, so the study is designed to include that number of people.^[1]

At Week 16, researchers will measure the main outcome and compare the results between the study treatment and the control group.^[1] This helps show whether NAV-240 gives meaningful improvement in hidradenitis suppurativa symptoms.^[1]

Table of Contents

• What are TIL cells?
• Which clinical trials and cancers are being studied?
• How TIL therapy is given in these studies
• What outcomes are measured (safety and effectiveness)
• Who may join these trials (common inclusion and exclusion themes)
• Immune tests and biomarkers studied

What are TIL cells?

TIL cells stands for tumor-infiltrating lymphocytes. These are immune cells, mainly T-cells, that are already inside a person’s tumor. The idea behind TIL therapy is to use these tumor-fighting cells as a treatment.

In the trials provided, TIL cells are described as a cell therapy product given by intravenous infusion (through a vein). One investigational version is called Meta10-TIL, described as “metabolically armed” TIL therapy for people with advanced solid tumors.

^[1]

Which clinical trials and cancers are being studied?

The provided trial data includes TIL-based approaches in several cancer settings:

• Advanced solid tumors: An open-label study evaluates the safety and signs of benefit of Meta10-TIL therapy in advanced solid tumors.

• Metastatic melanoma: A phase I/II, single-center study (ACTME) evaluates TIL therapy together with nivolumab, and later the combination of TIL plus low-dose PEG-IFNα plus nivolumab, for progressive unresectable stage III or stage IV melanoma.

• Ovarian carcinoma: A phase I/II trial (OVACURE-2) studies adoptive T cell therapy (using TIL cells) plus low-dose IL-2 as a first-line neoadjuvant strategy in stage III/IV epithelial high-grade ovarian, fallopian tube, or primary peritoneal cancer.

^[1][2][3]

How TIL therapy is given in these studies

Across the trials, the TIL product is given as an infusion into a vein.

• Meta10-TIL for advanced solid tumors: Participants receive nonmyeloablative lymphodepletion chemotherapy (a pre-treatment that reduces immune cells without fully wiping out bone marrow function) with cyclophosphamide and fludarabine, followed by Meta10-TIL infusion on day 0.

• ACTME in metastatic melanoma: The study evaluates safety and toxicity of TIL and nivolumab first, and later the combination of TIL, PEG‑IFNα, and nivolumab.

• OVACURE-2 in ovarian cancer: The study evaluates TIL-based adoptive T cell therapy plus low-dose IL-2, and aims to determine dosing for phase II based on dose-limiting toxicities (DLTs).

^[1][2][3]

What outcomes are measured (safety and effectiveness)

Safety outcomes

A central goal in these studies is to understand side effects. Trials measure adverse events (AEs) and grade them with CTCAE (a standard scale for severity).

• In the Meta10-TIL advanced solid tumor study, the primary outcome is adverse events graded by NCI CTCAE v5.0 over 1 year after infusion.

• In ACTME metastatic melanoma, safety and toxicity are evaluated using CTCAE 4.0, and certain grade 3 toxicities and serious adverse events may be considered acceptable if they do not lead to stopping treatment.

• In OVACURE-2 ovarian cancer, toxicity related to TIL plus low-dose IL-2 is assessed using NCI CTCAE v5.0, with a focus on grade greater than III and identifying DLTs to help choose a recommended dose for phase II.

^[1][2][3]

Effectiveness outcomes

These trials also look for signs the treatment may control cancer. Common measures include:

• Objective response rate (ORR): The percent of patients with a confirmed partial response (PR) or complete response (CR), often measured with RECIST v1.1.

• Duration of response (DOR): How long a PR or CR lasts before the cancer grows or the patient dies.

• Progression-free survival (PFS): Time until the cancer progresses or death occurs.

• Overall survival (OS): Time from a defined study point (for example, infusion date) to death.

• Disease control rate (DCR): Percent of patients with CR, PR, or stable disease (SD).

In the ACTME melanoma study, disease control is assessed with imaging such as CT and/or MRI using RECIST 1.1 and also immune-related response criteria (irRC), which are sometimes used in immunotherapy research to better capture immune-related patterns of tumor change.

^[1][2]

Who may join these trials (common inclusion and exclusion themes)

Each study has its own detailed rules. From the provided trial text, common themes include confirming the cancer type and stage, showing the cancer can be measured (or tracked) in standard ways, and making sure general health is strong enough for intensive immunotherapy approaches.

Examples of inclusion requirements described in the provided trials

• Confirmed diagnosis and stage (for example, metastatic melanoma stage III unresectable or stage IV; or epithelial high-grade ovarian/fallopian tube/primary peritoneal cancer stage III/IV).

• Measurable disease using RECIST v1.1 (some ovarian cancer participants may also qualify via elevated CA125 criteria as described).

• Functional status requirements such as WHO performance status ≤ 1 or ECOG performance status 0–1, meaning the person is fairly active and able to care for themselves.

• Laboratory values in acceptable ranges (blood counts and organ function measures), and negative viral testing for infections such as HIV, hepatitis B, and hepatitis C as specified.

Examples of exclusion considerations described in the provided trials

• Pregnancy or breastfeeding.

• Some forms of serious heart disease, such as NYHA Class III or IV.

• Active serious infections requiring antibiotics.

• Active immunodeficiency or autoimmune disease requiring immune-suppressing drugs (with vitiligo specifically noted as not excluding participation in these trials).

• Brain metastases limitations differ by study: the melanoma trial allows brain metastases only if neurologically stable for at least 2 months and without dexamethasone; the ovarian trial excludes brain metastases.

^[2][3]

Immune tests and biomarkers studied

Beyond tumor measurements and side effects, some trials include detailed immune research to understand why some patients respond better than others.

• The metastatic melanoma ACTME trial includes goals such as building a possible biomarker profile, comparing immune features in patients with and without response, and studying the infused T cell product using immunomonitoring. It also describes evaluating immune characteristics in PBMCs (blood immune cells) and exploring differences between CD8-rich and CD8-poor metastases, including using CD8-immunoPET/CT methods as described in the trial record.

• The ovarian cancer OVACURE-2 trial lists secondary objectives including immune monitoring with TCR clonotypes and tracking immune cell subsets such as CD8/CD4 and other immune cell categories named in the protocol summary.

• The Meta10-TIL advanced solid tumor trial includes plans to characterize pharmacokinetic (PK) and pharmacodynamic (PD) profiles, which broadly means tracking the therapy in the body over time and its biological effects.

^[1][2][3]

Table of Contents

• What is Tiotropium Bromide Monohydrate?
• What Conditions Does Tiotropium Treat?
• How is Tiotropium Administered?
• Clinical Studies on Tiotropium
• Effectiveness of Tiotropium
• Potential Side Effects and Considerations

What is Tiotropium Bromide Monohydrate?

Tiotropium Bromide Monohydrate is a medication that belongs to a class of drugs called long-acting muscarinic antagonists (LAMAs). It is primarily used to treat respiratory conditions by helping to relax and open the airways in the lungs^[1]. This medication is also known by its brand names, which include Spiriva HandiHaler and Spiriva Respimat^[2].

What Conditions Does Tiotropium Treat?

Tiotropium Bromide Monohydrate is primarily used to treat the following conditions:

• Chronic Obstructive Pulmonary Disease (COPD): This is a group of lung diseases that includes chronic bronchitis and emphysema, characterized by airflow blockage and breathing-related problems^[5].
• Asthma: While not its primary use, some studies have explored the effectiveness of tiotropium in managing allergic asthma^[4].

These conditions can significantly impact a patient’s quality of life, and tiotropium is designed to help manage symptoms and improve breathing.

How is Tiotropium Administered?

Tiotropium Bromide Monohydrate is administered through inhalation. There are several devices used to deliver the medication:

• Easyhaler: This is a dry powder inhaler that delivers tiotropium in doses of 10 micrograms^[1].
• HandiHaler: This device uses capsules containing 18 micrograms of tiotropium^[2].
• Respimat: This is a soft mist inhaler that delivers 2.5 micrograms of tiotropium per puff, with patients typically taking two puffs for a total dose of 5 micrograms^[4].

The medication is usually taken once daily, which helps improve patient adherence to the treatment regimen^[5].

Clinical Studies on Tiotropium

Several clinical studies have been conducted to evaluate the effectiveness and safety of Tiotropium Bromide Monohydrate:

• Pharmacokinetic Studies: These studies compare how the body absorbs and processes tiotropium from different inhaler devices. They measure factors like peak plasma concentration (Cmax) and area under the concentration-time curve (AUC) to understand how quickly and effectively the medication enters the bloodstream^[1][2][3].
• Efficacy Studies: Some studies have looked at how well tiotropium works against specific symptoms. For example, one study examined its effectiveness against allergen-induced early asthmatic responses in individuals with atopic asthma^[4].
• Observational Studies: These studies observe how adherence to tiotropium treatment affects patients’ health-related quality of life and COPD symptoms over time^[5].

Effectiveness of Tiotropium

The effectiveness of Tiotropium Bromide Monohydrate is measured in several ways:

• Lung Function: Tiotropium helps improve lung function by relaxing the airways, which is typically measured through tests like FEV1 (Forced Expiratory Volume in 1 second)^[4].
• Quality of Life: Studies have used questionnaires like the Clinical COPD Questionnaire (CCQ) to assess how tiotropium impacts patients’ overall health status and quality of life^[5].
• Exacerbations: Tiotropium has been shown to reduce the frequency of COPD exacerbations, which are sudden worsening of COPD symptoms^[5].
• Asthma Control: In asthma studies, tiotropium has shown potential in controlling allergen-induced asthmatic responses^[4].

Potential Side Effects and Considerations

While Tiotropium Bromide Monohydrate is generally well-tolerated, it’s important to be aware of potential side effects and considerations:

• Common Side Effects: These may include dry mouth, constipation, and upper respiratory tract infections.
• Adherence: The effectiveness of tiotropium depends on regular use. Studies have looked at reasons for non-adherence to help improve patient compliance^[5].
• Interactions: Always inform your healthcare provider about all medications you’re taking to avoid potential drug interactions.
• Proper Use: It’s crucial to use the inhaler device correctly. Your healthcare provider or pharmacist can demonstrate the proper technique.

As with any medication, it’s important to discuss the benefits and potential risks of Tiotropium Bromide Monohydrate with your healthcare provider to determine if it’s the right treatment for your specific condition.

Table of Contents

• What is Tazarotene?
• How Does Tazarotene Work?
• Conditions Treated with Tazarotene
• Formulations and Strengths
• Application Methods
• Efficacy in Treating Acne Vulgaris
• Efficacy in Treating Plaque Psoriasis
• Efficacy in Other Skin Conditions
• Potential Side Effects
• Special Considerations

What is Tazarotene?

Tazarotene is a prescription medication that belongs to a class of drugs known as retinoids, which are related to vitamin A. Specifically, it is classified as an acetylenic retinoid, which means it has a particular chemical structure that makes it effective for certain skin conditions. Tazarotene is available under various brand names, including Tazorac®, Fabior™, and Arazlo™, among others ^[1].

How Does Tazarotene Work?

Tazarotene works by normalizing skin cell development and reducing inflammation. When applied to the skin, tazarotene is converted to its active form, tazarotenic acid, which then binds to specific receptors in skin cells. This binding action helps to:

• Normalize the way skin cells grow and develop
• Reduce the influx of inflammatory cells into the skin
• Promote the shedding of dead skin cells, preventing pore blockage
• Stimulate collagen production, which may help with certain types of scarring

By affecting these processes, tazarotene can help manage various skin conditions characterized by abnormal skin cell growth or inflammation ^[2].

Conditions Treated with Tazarotene

Clinical trials have shown that tazarotene is effective in treating several skin conditions:

Acne Vulgaris

Acne vulgaris is a common skin condition characterized by comedones (blackheads and whiteheads), inflammatory lesions (papules, pustules, and nodules), and sometimes scarring. Tazarotene has been extensively studied for treating moderate to severe acne ^[3].

Plaque Psoriasis

Plaque psoriasis is a chronic autoimmune condition characterized by raised, red, scaly patches on the skin. Tazarotene helps reduce the thickness, scaling, and redness of psoriatic plaques ^[4].

Other Skin Conditions

Clinical trials have also investigated tazarotene for treating:

• Basal cell carcinoma (BCC) and basal cell nevus syndrome (BCNS): Studies have examined tazarotene’s potential as a chemopreventive agent for these conditions ^[5].
• Brittle nails: Tazarotene may help improve the condition of brittle fingernails ^[6].
• Atrophic post-acne scarring: Research suggests tazarotene might help improve the appearance of acne scars ^[7].
• Cutaneous T-cell lymphoma: Tazarotene has been studied as a treatment for this rare type of skin cancer ^[8].
• Hand-foot skin reaction (HFSR): Tazarotene may help prevent this side effect from certain cancer medications ^[9].
• Postinflammatory erythema (PIE) and postinflammatory hyperpigmentation (PIH): These are skin discolorations that can occur after acne heals ^[10].
• Nail psoriasis: Tazarotene has been studied for treating psoriasis affecting the nails ^[11].

Formulations and Strengths

Tazarotene is available in several formulations and strengths, allowing for tailored treatment approaches based on the condition being treated and individual patient factors:

• Cream: Available in 0.05% and 0.1% strengths
• Gel: Available in 0.05% and 0.1% strengths
• Foam: Available in 0.1% strength
• Lotion: Available in 0.045% and 0.1% strengths

Lower concentrations (0.045% or 0.05%) are often used for more sensitive skin or milder conditions, while higher concentrations (0.1%) may be prescribed for more severe cases ^[12].

Application Methods

How tazarotene is applied depends on the formulation and the specific condition being treated:

For Acne Vulgaris

• Apply a thin layer to clean, dry skin once daily, typically in the evening
• Some formulations (like DFD-03 lotion) may be applied twice daily for 1 minute and then rinsed off
• Treatment areas typically include the entire face, avoiding the eyes, lips, and mucous membranes
• Some patients may also apply to other affected areas such as the chest, back, and shoulders

For Plaque Psoriasis

• Apply a thin film to cover only the affected areas once daily
• Avoid application to unaffected skin
• Follow your doctor’s instructions regarding how long to leave the medication on

Your healthcare provider will give you specific instructions based on your condition, the formulation prescribed, and your individual skin characteristics ^[13].

Efficacy in Treating Acne Vulgaris

Multiple clinical trials have demonstrated the effectiveness of tazarotene for acne vulgaris:

Impact on Acne Lesions

Studies show that tazarotene significantly reduces both inflammatory lesions (papules, pustules, and nodules) and non-inflammatory lesions (open and closed comedones) in patients with acne. In clinical trials, patients typically experienced:

• Significant reduction in inflammatory lesion counts after 12 weeks of treatment
• Significant reduction in non-inflammatory lesion counts after 12 weeks of treatment
• Continued improvement with longer treatment duration

Global Assessment Improvement

Many patients achieve a clinical response of “success,” defined as an Investigator’s Global Assessment (IGA) score that is at least two grades less than the baseline assessment. This means their acne severity improved substantially during treatment ^[14].

Comparative studies have shown that tazarotene is effective in various formulations (cream, gel, foam, lotion), with newer formulations designed to minimize irritation while maintaining efficacy ^[15].

Efficacy in Treating Plaque Psoriasis

Tazarotene has demonstrated efficacy in treating plaque psoriasis in clinical studies:

Treatment Success Rates

In clinical trials, treatment success for psoriasis was defined as achieving a score of 0 (clear), 1 (minimal), or 2 (mild disease) on the Investigator’s Global Assessment (IGA) scale. Many patients achieved this level of improvement after 12 weeks of treatment ^[16].

Improvement in Psoriatic Features

Tazarotene helps improve specific features of psoriatic plaques:

• Reduction in plaque elevation (thickness)
• Decrease in scaling
• Lessening of erythema (redness)

These improvements are measured using the Psoriasis Area Severity Index (PASI), with many patients achieving scores of 1 or less (indicating clear or almost clear) for these parameters after treatment ^[17].

Efficacy in Other Skin Conditions

Basal Cell Carcinoma and Basal Cell Nevus Syndrome

Research suggests that tazarotene may help as a chemopreventive agent for basal cell carcinomas (BCCs) in patients with basal cell nevus syndrome (BCNS). In one study, topical tazarotene was applied over 18 months, and researchers evaluated whether it reduced the incidence of BCCs on treated skin ^[18].

Brittle Nails

In a study of tazarotene for brittle nails, patients applied the medication twice daily to affected fingernails for 24 weeks. Improvements were measured in roughness, raggedness, and peeling of the nails ^[19].

Atrophic Post-Acne Scarring

Clinical research has compared tazarotene to other treatments like microneedling for atrophic post-acne scars. Some studies suggest that daily application of tazarotene gel 0.1% may help improve the appearance of certain types of acne scars ^[20].

Postinflammatory Erythema and Hyperpigmentation

Tazarotene is being studied for its potential to treat postinflammatory erythema (skin reddening) and postinflammatory hyperpigmentation (dark spots) that can occur after acne lesions heal. The lower concentration formulation (0.045%) may be beneficial in reducing these discolorations with less irritation than higher concentrations ^[21].

Potential Side Effects

As with any medication, tazarotene can cause side effects. Common side effects include:

Local Skin Reactions

• Erythema (redness): May range from slight to moderate
• Dryness: The skin may become dry with continued use
• Peeling: Mild to moderate peeling of the skin is common
• Burning or stinging: Especially when first applied
• Itching: May occur in the treatment area

These side effects are typically most pronounced during the first few weeks of treatment and often decrease over time as your skin adjusts to the medication ^[22].

Less Common Side Effects

• Skin irritation
• Contact dermatitis
• Temporary worsening of acne or psoriasis initially
• Increased sensitivity to sunlight

If you experience severe irritation or an allergic reaction, discontinue use and contact your healthcare provider immediately ^[23].

Special Considerations

Sun Sensitivity

Tazarotene can make your skin more sensitive to sunlight. To protect your skin:

• Limit sun exposure, especially between 10 AM and 2 PM
• Use broad-spectrum sunscreen with SPF 30 or higher
• Wear protective clothing, hats, and sunglasses
• Avoid tanning beds and sunlamps

Pregnancy and Breastfeeding

Tazarotene is classified as pregnancy category X, meaning it should not be used during pregnancy as it may cause birth defects. Women of childbearing potential should use effective contraception during treatment. Discuss with your healthcare provider if you are pregnant, planning to become pregnant, or breastfeeding ^[24].

Combination Therapy

Tazarotene is sometimes used in combination with other treatments for enhanced effectiveness:

• For acne, it may be combined with topical antibiotics or benzoyl peroxide
• For psoriasis, it may be used alongside corticosteroids or phototherapy

Your healthcare provider will determine the most appropriate treatment approach for your specific condition ^[25].

New Research Applications

Ongoing research is exploring new potential uses for tazarotene:

• Treatment of idiopathic pulmonary fibrosis (IPF) with an oral formulation (GRI-0621)
• Prevention of hand-foot skin reaction in cancer patients receiving certain medications
• Treatment of postinflammatory pigmentation changes following acne

These applications are still being investigated in clinical trials and are not yet approved for routine clinical use ^[26].

Table of Contents

• What is Potassium Hydroxide?
• Understanding Molluscum Contagiosum
• How Potassium Hydroxide Treats Molluscum Contagiosum
• Clinical Research on Potassium Hydroxide
• How to Apply Potassium Hydroxide
• Possible Side Effects
• Treatment Effectiveness and Follow-up

What is Potassium Hydroxide?

Potassium hydroxide (KOH) is a chemical compound that is being studied as a topical treatment for certain skin conditions. In medical settings, it can be prepared as an aqueous solution (mixed with water) at different concentrations, such as 10% and 15%, for topical application on the skin^[1]. This compound is sometimes used in dermatology because of its ability to break down certain types of tissue.

Understanding Molluscum Contagiosum

Molluscum contagiosum is a viral skin infection that primarily affects children. As indicated by its name, it is highly contagious and can spread through direct skin contact or by touching contaminated objects^[1]. The infection causes small, raised bumps or lesions on the skin that may be flesh-colored, white, or pink.

While molluscum contagiosum is not a serious medical condition and often clears up on its own eventually, treatment may be recommended because:

• The infection is highly contagious and can spread to other parts of the body or to other people
• The visible lesions may cause aesthetic concerns
• Some children may experience psychological distress due to the appearance of the bumps

How Potassium Hydroxide Treats Molluscum Contagiosum

Potassium hydroxide works as a caustic agent when applied to the skin. This means it gradually breaks down the tissue of the molluscum lesions^[1]. By causing mild controlled damage to the affected area, it helps the body clear the viral infection. The treatment is aimed at the complete disappearance of lesions in the affected zones.

Clinical Research on Potassium Hydroxide

A double-blind, randomized clinical trial has been designed to test the effectiveness and tolerance of potassium hydroxide for treating molluscum contagiosum^[1]. The study compares three treatment groups:

1. 10% potassium hydroxide aqueous solution
2. 15% potassium hydroxide aqueous solution
3. Placebo (saline solution)

This research approach helps determine whether potassium hydroxide is truly effective compared to no treatment (placebo) and which concentration (10% or 15%) might offer the best balance of effectiveness and tolerability^[1].

How to Apply Potassium Hydroxide

In the clinical trial, the treatment consists of daily topical application of the potassium hydroxide solution to the affected areas^[1]. The medication is applied directly to the molluscum lesions, not to surrounding healthy skin. Always follow your healthcare provider’s specific instructions on how to apply this treatment, as improper application could cause skin damage.

Possible Side Effects

As part of the clinical research, several potential side effects of potassium hydroxide treatment are being monitored^[1], including:

• Hyperpigmentation: darkening of the skin at the treatment site
• Itching: an uncomfortable sensation that may cause a desire to scratch
• Burning sensation: a feeling of heat or burning at the application site
• Pain: discomfort at the site where the solution is applied

These side effects are being carefully evaluated to determine the overall tolerance of different concentrations of potassium hydroxide^[1].

Treatment Effectiveness and Follow-up

The main goal of potassium hydroxide treatment is the complete healing of molluscum contagiosum, defined as the disappearance of lesions in the affected areas^[1]. To properly evaluate this effectiveness, the clinical trial includes several follow-up visits at 15, 30, 45, and 60 days after starting treatment.

During these follow-up visits, healthcare providers assess^[1]:

• The surface area affected by the condition
• The number of lesions
• The size of individual lesions
• The density of lesions in affected areas
• Any recurrence of previously healed lesions

The natural progression of untreated molluscum contagiosum is also being studied in the placebo group to better understand how the infection evolves without intervention^[1].

Table of Contents

• What is Piclidenoson?
• How Piclidenoson Works
• Medical Conditions Treated with Piclidenoson
• Piclidenoson for COVID-19 Treatment
• Piclidenoson for Plaque Psoriasis Treatment
• Dosage and Administration
• Clinical Trials and Research
• Safety and Potential Side Effects

What is Piclidenoson?

Piclidenoson, also known as CF101, is an investigational oral medication that is being studied for the treatment of various medical conditions^[1]. It is administered as tablets taken by mouth and is currently undergoing clinical trials to evaluate its effectiveness and safety for different diseases^[2].

How Piclidenoson Works

Piclidenoson is classified as a selective A3AR agonist^[2]. This means it targets and activates a specific receptor in the body called the A3 adenosine receptor (A3AR). These receptors are involved in various biological processes, including inflammation regulation. By activating these receptors, Piclidenoson may help reduce inflammation, which is a key factor in diseases like psoriasis and potentially in the severe symptoms of COVID-19.

Medical Conditions Treated with Piclidenoson

Based on the clinical trials information, Piclidenoson is being investigated for two main conditions:

• COVID-19: For patients with moderate to severe coronavirus infection^[1]
• Plaque Psoriasis: For patients with moderate-to-severe plaque psoriasis (a chronic skin condition causing red, scaly patches)^[2]

Piclidenoson for COVID-19 Treatment

In the context of COVID-19 treatment, Piclidenoson is being studied in a randomized, double-blind, placebo-controlled trial^[1]. This means that some patients receive Piclidenoson while others receive a placebo (inactive substance), and neither the patients nor the researchers know who is receiving which treatment until the study is completed.

For COVID-19, the dosage being studied is 2 mg taken orally every 12 hours for up to 28 days, in addition to standard supportive care^[1].

The study aims to determine if Piclidenoson can help:

• Keep patients alive and free of respiratory failure (avoiding the need for mechanical ventilation or other advanced oxygen support)^[1]
• Increase the proportion of patients who can be discharged home without needing supplemental oxygen^[1]
• Improve clinical status according to a standardized scale^[1]
• Reduce the time needed for clinical improvement^[1]
• Decrease the need for mechanical ventilation or ICU admission^[1]
• Shorten hospital stays^[1]
• Reduce the duration of supplemental oxygen need^[1]
• Accelerate viral clearance (how quickly the virus is eliminated from the body)^[1]

Piclidenoson for Plaque Psoriasis Treatment

For psoriasis treatment, Piclidenoson is being evaluated in a Phase 3 clinical trial, which is one of the final stages of testing before a medication can be approved for general use^[2].

In this study, patients with moderate-to-severe plaque psoriasis are given Piclidenoson 3 mg twice daily^[2]. The effectiveness of the treatment is measured using several standardized scales:

• PASI (Psoriasis Area and Severity Index): A tool used to measure the severity and extent of psoriasis. A PASI 75 response means the patient’s psoriasis has improved by 75% or more^[2].
• sPGA (Static Physician’s Global Assessment): A physician’s rating of the overall severity of a patient’s psoriasis. The goal is to achieve a score of 0 or 1 (clear or almost clear skin) with at least a 2-point improvement from baseline^[2].
• PSSD (Psoriasis Symptoms and Signs Diary): A patient-reported measure of psoriasis symptoms and their impact on quality of life^[2].
• DLQI (Dermatology Life Quality Index): A questionnaire that measures how much a skin problem has affected a patient’s life^[2].

For some patients with specific areas affected, additional measurements may include:

• PSSI (Psoriasis Scalp Severity Index): For patients with scalp involvement^[2]
• NAPSI (Nail Psoriasis Severity Index): For patients with nail involvement^[2]

Dosage and Administration

Based on the clinical trials, the dosages being studied are:

• For COVID-19: 2 mg taken orally every 12 hours for up to 28 days^[1]
• For Plaque Psoriasis: 3 mg taken orally twice daily^[2]

In both cases, Piclidenoson is administered as tablets taken by mouth^[1][2].

Clinical Trials and Research

Piclidenoson is currently being studied in structured clinical trials. These are scientific studies designed to evaluate the safety and effectiveness of new medications in human subjects.

The COVID-19 trial (NCT04333472) is designed to enroll patients with moderate or severe COVID-19 who are hospitalized^[1]. Patients are monitored for up to 29 days to evaluate various outcomes including survival, respiratory status, need for mechanical ventilation, and time to hospital discharge.

The psoriasis trial (NCT06643260) is a more complex study conducted in multiple segments^[2]:

• Segment 1: A 16-week primary efficacy period where patients receive either Piclidenoson or placebo^[2]
• Segment 2 (for eligible patients): Includes three periods:
  1. Period A (Weeks 0-16): Primary efficacy testing^[2]
  2. Period B (Weeks 17-32): Patients initially on placebo switch to Piclidenoson^[2]
  3. Period C (Weeks 33-52): Some patients who responded well are randomly assigned to either continue Piclidenoson or switch to placebo to test durability of response^[2]

After completing the 52-week study, patients may have the opportunity to enroll in a long-term safety and efficacy trial lasting up to an additional 4 years^[2].

Safety and Potential Side Effects

As Piclidenoson is still in clinical trials, the full safety profile and all potential side effects are not yet fully established. Both trials are monitoring patients for adverse events (side effects)^[1][2].

The COVID-19 trial is specifically monitoring for:

• Treatment-emergent adverse events^[1]
• Serious adverse events^[1]
• Adverse events leading to withdrawal from the study^[1]
• Abnormalities in laboratory tests or electrocardiograms (ECGs)^[1]

Similarly, the psoriasis trial is monitoring for all adverse events throughout the study period^[2]. Both trials include regular safety assessments including physical examinations, vital signs monitoring, and laboratory tests.

It’s important to note that the safety monitoring in these trials is thorough and includes measures to protect patient well-being, including stopping rules that would halt a patient’s participation if certain safety concerns arise^[1].

Table of Contents

• What is Ixekizumab?
• How Does Ixekizumab Work?
• Conditions Treated with Ixekizumab
• How is Ixekizumab Administered?
• Effectiveness of Ixekizumab
• Potential Side Effects
• Ongoing Research and Potential New Uses

What is Ixekizumab?

Ixekizumab, also known by its brand name Taltz, is a prescription medication used to treat several inflammatory conditions^[1]. It belongs to a class of drugs called monoclonal antibodies, which are laboratory-produced molecules designed to serve as substitute antibodies that can restore, enhance, or mimic the immune system’s attack on specific cells^[2].

How Does Ixekizumab Work?

Ixekizumab works by targeting and blocking a specific protein in your body called interleukin 17A (IL-17A). This protein is involved in causing inflammation in various conditions. By inhibiting IL-17A, ixekizumab helps reduce inflammation and alleviate symptoms associated with certain inflammatory diseases^[2].

Conditions Treated with Ixekizumab

Ixekizumab is approved to treat several conditions, including:

• Plaque Psoriasis: A chronic skin condition characterized by red, scaly patches on the skin^[5].
• Psoriatic Arthritis: A type of inflammatory arthritis that affects some people with psoriasis^[6].
• Generalized Pustular Psoriasis: A rare and severe form of psoriasis characterized by widespread redness and pustules on the skin^[7].
• Erythrodermic Psoriasis: A severe form of psoriasis that affects most of the body surface^[7].

Additionally, researchers are investigating its potential use in other conditions such as:

• Idiopathic Subglottic Stenosis: A rare condition causing narrowing of the airway below the vocal cords^[1].
• Bullous Pemphigoid: An autoimmune blistering disease of the skin^[2].
• Pityriasis Rubra Pilaris: A rare inflammatory skin disease^[3].
• Treatment-Resistant Depression: A form of depression that doesn’t respond to standard treatments^[8].
• Type 1 Diabetes: An autoimmune condition affecting insulin production^[9].

How is Ixekizumab Administered?

Ixekizumab is administered as a subcutaneous (under the skin) injection. The dosing schedule can vary depending on the condition being treated, but generally follows this pattern:

• An initial higher dose (usually 160 mg) at the start of treatment.
• Followed by regular doses (usually 80 mg) every 2 or 4 weeks, depending on the condition and treatment phase^[1][4].

Your healthcare provider will determine the appropriate dosing schedule for your specific condition and needs.

Effectiveness of Ixekizumab

Clinical trials have shown ixekizumab to be effective in treating its approved conditions. For example:

• In plaque psoriasis, many patients achieve significant improvement in skin clearance, measured by scales such as the Psoriasis Area and Severity Index (PASI)^[5].
• For psoriatic arthritis, ixekizumab has shown to improve joint symptoms and physical function^[6].
• In generalized pustular psoriasis and erythrodermic psoriasis, ixekizumab has demonstrated effectiveness in reducing disease severity^[7].

Potential Side Effects

Like all medications, ixekizumab can cause side effects. Common side effects may include:

• Injection site reactions (redness, pain, or swelling at the injection site)
• Upper respiratory infections
• Nausea
• Fungal infections

More serious side effects, though rare, can occur. These may include serious allergic reactions or increased risk of infections. Always discuss potential side effects with your healthcare provider^[2].

Ongoing Research and Potential New Uses

Researchers are continually exploring new potential uses for ixekizumab. Some areas of ongoing research include:

• Idiopathic Subglottic Stenosis: Studies are investigating whether ixekizumab can reduce the need for repeated surgeries in this rare airway condition^[1].
• Bullous Pemphigoid: Research is examining if ixekizumab can effectively treat this autoimmune blistering disease^[2].
• Treatment-Resistant Depression: Scientists are exploring whether blocking IL-17A with ixekizumab could help patients with depression that hasn’t responded to other treatments^[8].
• Type 1 Diabetes: A study is investigating if ixekizumab can help preserve insulin production in newly diagnosed type 1 diabetes patients^[9].

These studies highlight the potential versatility of ixekizumab in treating various inflammatory and autoimmune conditions. However, it’s important to note that these are still under investigation and not approved uses of the medication.

Table of Contents

• What is IPN01195?
• What Conditions Does IPN01195 Treat?
• Clinical Trial Design
• How IPN01195 is Administered
• Safety Assessment
• How Effectiveness is Being Measured
• Food Effects on IPN01195
• What to Expect as a Trial Participant

What is IPN01195?

IPN01195 is a new investigational medication that is currently being studied for the treatment of advanced solid tumors^[1]. This drug is in the early stages of clinical development, specifically in a Phase I/II clinical trial, which means it is not yet approved for general use. The trial represents the first time this medication is being tested in humans (known as a first-in-human study).

What Conditions Does IPN01195 Treat?

IPN01195 is being investigated for the treatment of advanced solid tumors^[1]. These are cancers that:

• Form in solid organs or tissues (as opposed to blood cancers)
• Have spread from their original site to nearby tissues (locally advanced)
• May have spread to other parts of the body (metastatic)

The current clinical trial is not limited to a specific type of solid tumor, suggesting that researchers are investigating the drug’s potential effectiveness across multiple cancer types.

Clinical Trial Design

The clinical trial for IPN01195 (identified as NCT06833008) is structured as an open-label, Phase I/II study^[1]. “Open-label” means that both the participants and researchers know which treatment is being given. The study is divided into two main phases:

Phase I

This initial phase is further split into two parts:

• Part A (Dose Escalation): This part aims to find the safe dose range that shows activity against tumors. Different dose levels will be tested to determine how much of the drug patients can tolerate^[1].
• Part B (Dose Confirmation): After finding potentially effective doses in Part A, this segment will further assess how the drug works at either a “low dose” or “high dose” level. Participants will be randomly assigned to one of these dose groups^[1].

Phase II

Based on the results from Phase I, the study will continue to a Phase II extension. This phase will further evaluate the drug’s effectiveness and safety at the optimal dose determined in the earlier phase^[1].

How IPN01195 is Administered

The clinical trial documents indicate that IPN01195 will be administered at assigned dose levels, though the specific route of administration (such as oral or intravenous) is not explicitly stated in the available information^[1]. However, since the study includes food effect assessments (comparing the drug’s absorption when taken with or without food), it’s likely that IPN01195 is administered orally.

Safety Assessment

A primary focus of this clinical trial is to evaluate the safety of IPN01195. Several safety measurements are being tracked^[1]:

• Dose-Limiting Toxicities (DLTs): These are side effects serious enough to prevent increasing the dose further. The study measures the percentage of participants experiencing DLTs within 28 days of their first dose.
• Treatment Emergent Adverse Events (TEAEs): These are any unfavorable medical occurrences that begin after starting the study medication, whether or not they’re believed to be related to the drug.
• Serious Adverse Events: These are more severe side effects that may require hospitalization or are life-threatening.
• Dose Interruptions and Treatment Discontinuations: The study tracks how often treatment needs to be paused or stopped completely due to side effects.
• QT Interval Prolongation: The study monitors for potential effects on heart rhythm, specifically looking at the QT interval (a measurement on an electrocardiogram that indicates how long it takes for the heart to recharge between beats).

How Effectiveness is Being Measured

The study uses several standard measurements to assess how well IPN01195 works against cancer^[1]:

• Objective Response Rate (ORR): This is the percentage of participants whose tumors shrink or disappear completely. A “complete response” means all detectable cancer has disappeared, while a “partial response” means the tumor has shrunk by a defined percentage.
• Duration of Response (DoR): For patients whose tumors do respond to treatment, this measures how long that response lasts before the cancer starts growing again.
• Progression-Free Survival (PFS): This is the time from starting treatment until the cancer starts growing again or the patient dies.
• PFS Rate at 4 Months: The proportion of participants who are still alive and whose cancer has not progressed 4 months after starting treatment.
• Disease Control Rate (DCR): This includes patients whose best response is complete response, partial response, or stable disease (tumor neither growing nor shrinking significantly).

Food Effects on IPN01195

Part of the study evaluates how food affects the way the body processes IPN01195^[1]. This assessment compares:

• How quickly the drug reaches its maximum concentration in the blood (Tmax)
• The highest concentration it reaches (Cmax)
• The total exposure to the drug over time (AUC – Area Under the Curve)

These measurements are compared when the drug is taken in a fasted state (without food) versus a fed state (with food). This information helps determine whether future patients should take the medication with or without food for optimal effectiveness.

What to Expect as a Trial Participant

Participants in the IPN01195 clinical trial can expect^[1]:

• Screening Period: Initial assessments to determine eligibility for the study.
• Treatment Period: At least two visits during the first month, followed by monthly visits.
• Tumor Assessments: Every 6 weeks up to Week 24, then every 12 weeks afterward to measure how the tumor is responding to treatment.
• End of Treatment Visit: Occurring 30 days after the last dose of the study drug.
• Monitoring Procedures: Regular blood samples, urine collections, physical examinations, and clinical evaluations throughout the study.

The total duration of the study may be up to approximately 3 years, depending on how well participants respond to the treatment.

Table of contents

• Trial overview
• Study design and phase
• Who could participate
• What was measured
• Study status and size

Trial overview

The clinical trial for INF904 studied people with moderate to severe chronic spontaneous urticaria (CSU) or moderate to severe hidradenitis suppurativa (HS).^[1] The study was designed to look at safety and pharmacokinetics, which means how the body handles the study drug over time.^[1]

This was an interventional study, so participants received the study treatment and researchers measured the results.^[1] It was also an open-label basket study, meaning the treatment was known to both the researchers and the participants, and the same study included more than one patient group.^[1]

Study design and phase

The trial was a Phase 2 study.^[1] Phase 2 trials usually focus on safety and early signs of benefit in a specific group of patients, which fits the goal of this study.^[1]

Participants received INF904 by mouth, which is called oral treatment.^[1] The brief summary says the study looked at safety after multiple oral doses in subjects with CSU or HS.^[1]

Who could participate

The study targeted subjects with moderate to severe chronic spontaneous urticaria or moderate to severe hidradenitis suppurativa.^[1] These are long-lasting conditions that can cause major symptoms and affect daily life.

• People with CSU had a skin condition with hives that come and go without a clear trigger.^[1]

• People with HS had a long-term inflammatory skin disease, and the study focused on those with moderate to severe disease.^[1]

What was measured

The main outcome was the frequency, severity, and relatedness of treatment-emergent adverse events and serious adverse events using MedDRA classification.^[1] In simple terms, the study tracked new medical problems that started or got worse after treatment began, and it also tracked whether those problems were serious.^[1]

The study also evaluated pharmacokinetics, which helps researchers understand how the body absorbs, processes, and removes INF904.^[1]

Study status and size

The trial is marked as completed, so the planned study activities have already finished.^[1] The enrollment was 75 participants.^[1]

Only one trial record was provided, so the current clinical trial picture for INF904 in the source data is limited to this Phase 2 study in CSU and HS.^[1]

Table of Contents

• What is Cyclizine Hydrochloride?
• How Cyclizine Works
• Medical Uses of Cyclizine
• Cyclizine in Bariatric Surgery
• Cyclizine for Cesarean Section Patients
• Comparison with Other Medications
• How Cyclizine is Administered
• Risk Factors for Nausea and Vomiting

What is Cyclizine Hydrochloride?

Cyclizine Hydrochloride is a medication primarily used to prevent and treat nausea and vomiting. It belongs to a class of drugs known as antihistamines, specifically H1-receptor antagonists. Cyclizine is a piperazine derivative that works by blocking certain receptors in the body that trigger nausea and vomiting^[1]. This medication is commonly used in various medical settings where patients might experience nausea and vomiting, such as after surgery or during motion sickness.

How Cyclizine Works

Cyclizine works through several mechanisms in the body to prevent nausea and vomiting:

• It primarily acts as a histamine H1-receptor antagonist, blocking the action of histamine, which can trigger nausea^[1]
• It has some effect on dopamine D2 receptors^[1]
• It affects cholinergic receptors in the body^[1]
• It inhibits the integrative function of the vestibular nuclei (parts of the brain involved in balance and spatial orientation)^[1]

Although researchers haven’t fully explained all the ways cyclizine prevents nausea and vomiting, its central anticholinergic properties (blocking certain nerve signals) are partially responsible for its effectiveness. The medication also has central nervous system depressant and local anesthetic effects. Once in the body, cyclizine is metabolized (broken down) to its derivative called norcyclizine, which has little antihistamine activity compared to cyclizine itself^[2].

Medical Uses of Cyclizine

Cyclizine is prescribed for several conditions involving nausea and vomiting:

• Postoperative nausea and vomiting (PONV) – preventing sickness after surgery^[2]
• Motion sickness – preventing or treating nausea related to travel^[2]
• Drug-induced nausea – treating nausea caused by other medications^[2]
• Vertigo – managing dizziness in diseases affecting the vestibular apparatus (the balance system in your inner ear)^[2]

Cyclizine can be administered by mouth (orally) or given as an injection (parenterally), depending on the patient’s condition and needs^[2].

Cyclizine in Bariatric Surgery

Bariatric surgery (weight loss surgery) patients often experience significant postoperative nausea and vomiting. This can delay recovery by preventing patients from eating normally and moving around after surgery, which may lead to longer hospital stays^[1].

Several factors contribute to the high rate of nausea and vomiting after bariatric surgery:

• Obesity itself
• Presence of hiatal hernia (when part of the stomach pushes up into the chest)
• Direct stomach irritation from surgical trauma
• Presence of blood and secretions in the stomach
• Abdominal insufflation (inflation of the abdomen with gas during surgery)
• Surgical duration exceeding 1 hour
• The use of opioid pain medications^[1]

Recent research has been comparing the effectiveness of Cyclizine versus other medications such as Metoclopramide in reducing gastric residual volume (GRV) in bariatric surgery patients. GRV refers to the amount of fluid remaining in the stomach and is considered a predictor of postoperative nausea and vomiting. By measuring GRV using ultrasound, doctors can assess how well these medications are working to improve stomach emptying^[1].

Cyclizine for Cesarean Section Patients

Cyclizine is also being studied for use in patients undergoing cesarean section (C-section) who receive intrathecal morphine (morphine injected into the spinal fluid) for pain control. This type of pain control can frequently cause nausea and vomiting as side effects^[2].

In this context, cyclizine (50 mg given intravenously) is being compared with dexamethasone (a steroid medication) for preventing nausea and vomiting. The medication is typically administered within 1-2 minutes after the umbilical cord is clamped during the C-section procedure to ensure it doesn’t affect the baby^[2].

Comparison with Other Medications

Cyclizine is considered a “second-line” anti-nausea medication in some treatment protocols. This means it may be used when first-line medications aren’t sufficient or appropriate^[2].

First-line anti-nausea medications typically include:

• Serotonin antagonists (like ondansetron)
• Corticosteroids (like dexamethasone)
• Dopamine antagonists (like droperidol)^[2]

These medications work by different mechanisms and can reduce the risk of nausea and vomiting by about 25% each. They can be used in combination for better effects^[2].

In bariatric surgery, cyclizine is being compared with metoclopramide, which is a dopamine receptor antagonist that also has effects on bowel transit time and serotonin receptors at high doses^[1].

How Cyclizine is Administered

Cyclizine can be administered in several ways:

• Oral form – taken by mouth as tablets
• Intravenous (IV) form – injected directly into a vein

In the clinical trials described, cyclizine was administered intravenously at a dose of 50 mg^[1][2]. For bariatric surgery patients, it was delivered in a 10 mL syringe^[1], while for cesarean section patients, it was given within 1-2 minutes after the umbilical cord was clamped^[2].

Risk Factors for Nausea and Vomiting

Understanding the risk factors for postoperative nausea and vomiting can help you know why cyclizine might be prescribed. These risk factors fall into two main categories^[2]:

Patient-related risk factors:

• Female gender – women are three times more likely than men to experience postoperative nausea and vomiting
• Age – for adults, the risk decreases with age; for children, those older than 3 years have an increased risk compared to younger children
• Obesity – patients with a body mass index (BMI) over 30 have double the risk
• Non-smoking status – non-smokers have roughly double the risk (one theory suggests chemicals in cigarette smoke increase the metabolism of substances that cause nausea)
• History of gastrointestinal disease – conditions like gastritis or ulcers increase the risk
• Previous history – prior motion sickness, Meniere’s disease, or previous postoperative nausea and vomiting indicates a general susceptibility^[2]

Anesthesia-related risk factors:

• Volatile anesthetics – use of these gases doubles the risk, with risk increasing with higher doses
• Opioid use – both during and after surgery increases the risk in a dose-dependent manner by reducing muscle tone and peristaltic activity, delaying stomach emptying
• Duration of anesthesia – longer exposure to anesthetics and opioids increases risk^[2]

Knowing these risk factors can help your healthcare provider determine whether preventive anti-nausea medications like cyclizine might be beneficial for you before or after a surgical procedure^[2].

Table of Contents

• What is Dantrolene Sodium?
• Medical Uses of Dantrolene Sodium
• How Dantrolene Sodium Works
• How Dantrolene Sodium is Administered
• Potential Side Effects
• Ongoing Research and Potential Future Uses

What is Dantrolene Sodium?

Dantrolene Sodium, also known by brand names such as Dantrium, Ryanodex, or Revonto, is a medication primarily used as a muscle relaxant^[1]. It has been approved by the U.S. Food and Drug Administration (FDA) and has been in clinical use for over 30 years^[2]. Dantrolene is unique in its mechanism of action, which makes it effective for treating certain specific conditions.

Medical Uses of Dantrolene Sodium

Dantrolene Sodium is used to treat or prevent several medical conditions:

• Malignant Hyperthermia: This is the primary approved use of Dantrolene. Malignant hyperthermia is a rare but life-threatening condition that can occur during surgery, causing a rapid increase in body temperature and severe muscle contractions^[3].
• Exertional Heat Stroke: Research is ongoing to evaluate Dantrolene’s effectiveness in treating this severe form of heat-related illness^[4].
• Cerebral Vasospasm: Studies are investigating the use of Dantrolene in treating this complication of subarachnoid hemorrhage (bleeding in the brain)^[2][5].
• Wolfram Syndrome: This is a rare genetic disorder, and Dantrolene is being studied as a potential treatment^[6].
• Ventricular Arrhythmias: Research is exploring Dantrolene’s potential in treating certain types of irregular heart rhythms^[7].

How Dantrolene Sodium Works

Dantrolene Sodium works by affecting how calcium is released in muscle cells. Specifically, it inhibits a protein called RyR2 (ryanodine receptor 2)^[7]. By doing this, Dantrolene can help relax muscles and reduce excessive muscle contractions. This mechanism is particularly important in treating conditions like malignant hyperthermia and potentially in other disorders where muscle function or calcium regulation plays a role.

How Dantrolene Sodium is Administered

Dantrolene Sodium is typically administered in the following ways:

• Intravenous (IV) Injection: In emergency situations, such as during a malignant hyperthermia crisis or in research settings for other conditions, Dantrolene is often given as an IV injection^[4][7].
• Oral Medication: For some applications, Dantrolene may be given as an oral medication^[1].

The dosage and frequency of administration can vary depending on the specific condition being treated and the individual patient’s needs.

Potential Side Effects

Like all medications, Dantrolene Sodium can have side effects. Some potential side effects that have been observed in clinical trials include:

• Liver Function Changes: Doctors may monitor liver function tests while a patient is on Dantrolene^[6].
• Muscle Weakness: As Dantrolene affects muscle function, it may cause temporary weakness^[7].
• Changes in Blood Pressure: Some studies have monitored blood pressure changes in patients receiving Dantrolene^[2].
• Respiratory Effects: In some cases, Dantrolene may affect breathing, which is why respiratory function is often monitored during treatment^[7].

It’s important to note that the occurrence and severity of side effects can vary between individuals and depend on the condition being treated.

Ongoing Research and Potential Future Uses

Researchers are continually studying Dantrolene Sodium to understand its full potential. Some areas of ongoing research include:

• Neuroprotection: Studies are investigating whether Dantrolene could help protect brain cells in conditions like subarachnoid hemorrhage^[5].
• Cardiac Arrhythmias: Research is exploring Dantrolene’s potential effects on heart rhythm disorders^[7].
• Rare Genetic Disorders: The potential of Dantrolene in treating rare conditions like Wolfram Syndrome is being studied^[6].
• Heat-Related Illnesses: Dantrolene’s effectiveness in treating severe heat stroke is under investigation^[4].

These ongoing studies may lead to new approved uses for Dantrolene Sodium in the future, potentially benefiting patients with a wider range of conditions.

Table of Contents

• What is Brensocatib?
• How Does Brensocatib Work?
• Medical Conditions Being Treated with Brensocatib
• Dosage Forms Available
• Overview of Clinical Studies
• Safety and Potential Side Effects
• Special Considerations
• Ongoing Research

What is Brensocatib?

Brensocatib (also known as INS1007 or AZD7986) is an investigational medication being developed for various inflammatory conditions ^[1]. It is not yet fully approved for widespread use, but is currently undergoing extensive clinical testing to determine its effectiveness and safety for several medical conditions. Brensocatib is being studied primarily as an oral medication (taken by mouth) that works differently from many existing treatments by targeting a specific enzyme in the body ^[2].

How Does Brensocatib Work?

Brensocatib works through a unique mechanism of action. It is a selective, competitive, and reversible inhibitor of an enzyme called dipeptidyl peptidase 1 (DPP1, also known as cathepsin C) ^[3]. This enzyme plays an important role in activating certain proteins called neutrophil serine proteases during the maturation of neutrophils (a type of white blood cell) in the bone marrow.

When Brensocatib blocks DPP1, it prevents the activation of neutrophil proteases like neutrophil elastase, proteinase-3, and cathepsin-G. These proteases are normally released by neutrophils during inflammation and can cause tissue damage. By reducing the activity of these proteases, Brensocatib aims to decrease inflammation and tissue damage in various inflammatory conditions ^[4].

Unlike many anti-inflammatory treatments that work immediately, Brensocatib takes some time to show its full effect. This is because it needs time to replace the existing neutrophils with new ones that have lower levels of active proteases. Clinical studies have shown that significant reductions in neutrophil elastase concentrations can be observed after 14 days of treatment, with even greater reductions after 28 days ^[3].

Medical Conditions Being Treated with Brensocatib

Non-Cystic Fibrosis Bronchiectasis (NCFBE)

The most advanced research on Brensocatib is for the treatment of non-cystic fibrosis bronchiectasis (NCFBE). Bronchiectasis is a chronic condition where the airways in the lungs become damaged and widened, leading to symptoms such as chronic cough, excessive mucus production, and recurring lung infections ^[5].

In a Phase 2 clinical trial known as the WILLOW study, Brensocatib showed promising results in reducing the rate of pulmonary exacerbations (sudden worsening of symptoms) in people with NCFBE over a 24-week treatment period. This study tested doses of 10 mg and 25 mg once daily ^[5].

The research has progressed to Phase 3 with the ASPEN study, which is evaluating the effects of Brensocatib (10 mg and 25 mg) compared to placebo over a 52-week treatment period. This study is measuring how Brensocatib affects the rate of pulmonary exacerbations, lung function, and quality of life in NCFBE patients ^[6].

Cystic Fibrosis

Brensocatib is also being studied for potential benefits in people with cystic fibrosis, a genetic disorder that affects the lungs and digestive system. A Phase 2a study is evaluating the safety, tolerability, and pharmacokinetics (how the drug moves through the body) of Brensocatib in adults with cystic fibrosis at doses of 10 mg, 25 mg, 40 mg, and potentially 65 mg ^[7].

COVID-19

During the COVID-19 pandemic, Brensocatib was studied as a potential treatment for severe COVID-19. The STOP-COVID19 trial investigated whether Brensocatib could reduce the incidence of acute lung injury and acute respiratory distress syndrome (ARDS) in hospitalized COVID-19 patients by blocking damaging neutrophil proteases ^[3].

Hidradenitis Suppurativa

More recently, Brensocatib is being evaluated for hidradenitis suppurativa, a chronic inflammatory skin condition that causes painful bumps under the skin in areas where skin rubs together. The CEDAR study is a Phase 2b trial evaluating the efficacy and safety of Brensocatib at doses of 10 mg and 40 mg in adults with moderate to severe hidradenitis suppurativa ^[8].

Chronic Rhinosinusitis Without Nasal Polyps

Brensocatib is being studied for chronic rhinosinusitis without nasal polyps (CRSsNP), a condition characterized by inflammation of the sinuses that lasts 12 weeks or longer. The BiRCh study is examining whether Brensocatib (10 mg and 40 mg) can improve clinical symptoms of CRSsNP when used alongside mometasone furoate nasal spray ^[9].

Dosage Forms Available

Based on the clinical trials, Brensocatib is being developed in several dosage forms:

• Oral tablets: Most studies are using film-coated tablets at doses of 10 mg, 25 mg, or 40 mg taken once daily ^{[6] [8]}.
• Oral solution: A pediatric oral solution is being developed and compared to the tablet form in bioavailability studies ^[10].
• Different oral liquid formulations: Studies are evaluating the palatability (taste) and acceptability of different Brensocatib oral liquid formulations ^[11].

Overview of Clinical Studies

Brensocatib is undergoing extensive clinical testing to evaluate its effectiveness, safety, and how it works in the body:

Efficacy Studies

• WILLOW Study: A completed Phase 2 study in NCFBE that showed Brensocatib could extend the time to first pulmonary exacerbation and reduce the frequency of exacerbations ^[5].
• ASPEN Study: An ongoing Phase 3 study in NCFBE evaluating the effect of Brensocatib on the rate of pulmonary exacerbations over 52 weeks ^[6].
• CEDAR Study: A Phase 2b study in hidradenitis suppurativa evaluating whether Brensocatib can reduce the number of inflammatory nodules and abscesses ^[8].
• BiRCh Study: A Phase 2b study in chronic rhinosinusitis without nasal polyps measuring improvements in sinus symptoms ^[9].

Pharmacokinetic and Safety Studies

Several studies are investigating how Brensocatib is processed by the body and potential interactions with other medications:

• Studies in participants with kidney impairment ^[12]
• Studies in participants with liver impairment ^[13]
• Studies of drug interactions with medications like clarithromycin (an antibiotic) ^[14], rifampin, and esomeprazole ^[15]
• Studies of the absorption, metabolism, and excretion of Brensocatib ^[16]
• Studies evaluating potential effects on heart rhythm (QT interval) ^[17]

Safety and Potential Side Effects

As Brensocatib is still being investigated in clinical trials, the full safety profile and list of side effects are not yet fully established. The clinical trials mentioned are carefully monitoring for adverse events, which are any undesirable experiences associated with the use of the medication.

The safety evaluation includes monitoring:

• Number of participants who experience adverse events ^[6]
• Laboratory tests of blood counts, liver function, and kidney function ^[3]
• Specific adverse events of special interest, which in some studies include hyperkeratosis (thickening of the skin), infections, and dental complications ^[3]

Since Brensocatib works by affecting neutrophil function, which is important for fighting infections, researchers are carefully monitoring for any increased risk of infections in study participants.

Special Considerations

Kidney and Liver Function

Specific studies are being conducted to understand how Brensocatib affects patients with impaired kidney or liver function. These studies will help determine if dose adjustments are needed for these populations ^{[12] [13]}.

Drug Interactions

Studies are investigating potential interactions between Brensocatib and other medications, particularly those that affect specific liver enzymes called CYP3A4, which are involved in processing many medications. For example, a study is looking at how clarithromycin, a strong CYP3A4 inhibitor, affects Brensocatib levels in the body ^[14].

Administration with Food

Some studies specify that Brensocatib should be taken before breakfast, suggesting that food might affect how the drug is absorbed ^[5]. However, specific recommendations will be based on the results of ongoing studies.

Ongoing Research

Brensocatib research is ongoing across multiple fronts:

• Expanding to new patient populations, including children (pediatric formulations are in development) ^{[10] [11]}
• Testing in new medical conditions
• Long-term safety and efficacy monitoring
• Investigating optimal dosing regimens
• Developing new formulations for different patient needs

An expanded access program has been established for NCFBE patients who completed the ASPEN clinical trial, allowing them continued access to Brensocatib while research continues ^[18].

As research progresses, more information will become available about the effectiveness and safety of Brensocatib for various conditions. Patients interested in Brensocatib should discuss with their healthcare provider whether participation in a clinical trial might be appropriate for their specific situation.

Table of Contents

• What is AVTX-009?
• What is Hidradenitis Suppurativa?
• Clinical Trial Details
• How is AVTX-009 Administered?
• How is the Effectiveness of AVTX-009 Being Measured?
• Safety Monitoring

What is AVTX-009?

AVTX-009 is an investigational drug that is currently being studied for the treatment of moderate to severe Hidradenitis Suppurativa (HS). It is being evaluated in a clinical trial to determine if it can safely and effectively treat the symptoms of this painful skin condition. The drug is administered through subcutaneous injection, which means it is injected under the skin.^[1]

While the specific mechanism of how AVTX-009 works is not detailed in the available information, it is being studied as a potential treatment option for patients who suffer from HS, a chronic inflammatory skin condition. The trial aims to compare AVTX-009 against a placebo to determine its effectiveness and safety profile.^[1]

What is Hidradenitis Suppurativa?

Hidradenitis Suppurativa (HS) is a chronic, inflammatory skin condition characterized by painful bumps that appear in areas where skin rubs together, such as the armpits, groin, buttocks, and under the breasts. These bumps can become very painful and may break open, releasing fluid and developing into tunnels under the skin.^[1]

The severity of HS can be classified as follows:

• Mild: Total International HS Severity Score System (IHS4) score of 3 or less
• Moderate: IHS4 score of 4 to 10
• Severe: IHS4 score of 11 or higher

The IHS4 score is calculated by adding the number of nodules (multiplied by 1), the number of abscesses (multiplied by 2), and the number of draining tunnels (multiplied by 4).^[1]

Clinical Trial Details

AVTX-009 is being evaluated in a Phase 2 clinical trial called LOTUS. This is a randomized, double-blind, placebo-controlled, parallel-group study. Let’s break down what these terms mean:^[1]

• Phase 2: This phase of clinical research focuses on determining the effectiveness of a drug for a specific medical condition and continues to evaluate its safety.
• Randomized: Participants are randomly assigned to receive either AVTX-009 or a placebo.
• Double-blind: Neither the participants nor the researchers know who is receiving the actual drug versus the placebo during the study.
• Placebo-controlled: Some participants receive a placebo (an inactive substance) instead of the study drug to compare outcomes.
• Parallel-group: Different groups of participants receive different treatments simultaneously.

The trial consists of three parts:^[1]

1. A Screening Period lasting up to 28 days to determine eligibility
2. A Treatment Period of up to 16 weeks
3. A Follow-up Period of 6 weeks after the last dose

The maximum duration of participation in the trial is 24 weeks. Participants are randomly assigned in a 1:1:1 ratio to one of three groups:^[1]

• AVTX-009 Regimen 1
• AVTX-009 Regimen 2
• Matching placebo

How is AVTX-009 Administered?

In the clinical trial, AVTX-009 is administered in two different regimens:^[1]

• Regimen 1: AVTX-009 is given as a subcutaneous injection (an injection under the skin) every 4 weeks.
• Regimen 2: AVTX-009 is given as a subcutaneous injection every 2 weeks.

The placebo group receives matching placebo injections every 2 weeks. These different dosing schedules will help researchers determine the most effective and safe dosing regimen for AVTX-009.^[1]

How is the Effectiveness of AVTX-009 Being Measured?

The clinical trial uses several measurements to evaluate how well AVTX-009 works for treating HS. The primary measurement is:^[1]

Hidradenitis Suppurativa Clinical Response 75 (HiSCR75): This is defined as at least a 75% reduction in the total abscess and inflammatory nodule count, with no increase in abscess count and no increase in draining fistula count, compared to the beginning of the study (baseline).^[1]

Additional measurements include:

• HiSCR50: At least a 50% reduction in total abscess and inflammatory nodule count, with no increase in abscess or draining fistula counts.^[1]
• HiSCR90: At least a 90% reduction in total abscess and inflammatory nodule count, with no increase in abscess or draining fistula counts.^[1]
• Change from baseline in International HS Severity Score System (IHS4).^[1]
• Change from baseline in total abscess and inflammatory nodule (AN) count. An abscess is a collection of pus associated with swelling, redness, and other signs of inflammation. An inflammatory nodule is a raised, deep-seated, round bump, greater than 10 mm in diameter that is tender and red without evidence of containing fluid that can be drained.^[1]
• Change from baseline in draining fistula count. A draining fistula is a pathway connecting to the skin surface that drains fluid, either spontaneously or when gently pressed.^[1]
• Percentage of patients achieving at least a 30% reduction and at least a 1-unit reduction from baseline on the Numerical Rating Scale (NRS) in Patient’s Global Assessment of Skin Pain. This measures pain on a scale from 0 (no pain) to 10 (worst pain imaginable).^[1]
• Percentage of patients with flares, defined as a 25% or greater increase in abscess and inflammatory nodule count plus an increase of 2 or more compared to baseline.^[1]

Safety Monitoring

The safety and tolerability of AVTX-009 are being closely monitored throughout the clinical trial. This includes:^[1]

• Tracking the incidence of adverse events (AEs), which are any unfavorable medical occurrences in a participant receiving the drug.
• Monitoring for the development of anti-drug antibodies (ADA), which are antibodies that the body might produce against AVTX-009. The development of these antibodies could potentially affect how well the drug works or cause immune reactions.

Safety monitoring continues from the start of treatment through the 6-week follow-up period (up to Week 20).^[1]

In this early‑stage trial, volunteers are randomly placed into one of the two groups, and the staff who evaluate the results do not know which treatment each person received (blind assessment). Over several weeks, participants come to the clinic for visits where the ointment is applied, basic checks such as pulse and blood pressure are taken, and simple lab tests are performed to look for any side effects. The wound area is inspected regularly for irritation, and overall health is monitored throughout the study period.

Table of contents

• Trial overview
• Study design and participants
• What was measured
• Trial status and size
• Patient-friendly terms

Trial overview

This clinical research studied [14C] DC-806 in a Phase 1 setting.^[1]

The trial focused on healthy male participants and looked at how the study drug was removed from the body after one oral dose.^[1]

The brief summary says the study aimed to assess the rate and routes of excretion, including mass balance, and to assess pharmacokinetics in whole blood and plasma.^[1]

Study design and participants

This was an interventional study, which means researchers gave the study drug and then measured the body’s response.^[1]

The trial enrolled 8 participants and was completed.^[1]

The treatment listed in the source data was oral DC-806 and oral [14C]-DC-806, given as a single dose in the study summary.^[1]

What was measured

The main outcomes included how much of the total radioactive material and DC-806 was recovered in urine and feces.^[1]

The study also measured pharmacokinetic values in whole blood and plasma, including Cmax (the highest level), tmax (the time to reach the highest level), kel (the rate of removal), t1/2 (half-life), and AUC (total exposure over time).^[1]

For DC-806, the study also listed CL/F and Vz/F, which are measurements used to describe how the body clears a drug and how it spreads in the body.^[1]

For total radioactive material, the study measured whole blood to plasma ratios for Cmax and AUC0-inf, which help compare levels in different blood samples.^[1]

Trial status and size

The study status was Completed.^[1]

The enrollment was small, with only 8 healthy male participants, which is typical for an early Phase 1 study focused on how the body handles a substance rather than on disease treatment.^[1]

Patient-friendly terms

Excretion balance means checking where the study material goes after dosing and how much leaves the body through urine and feces.^[1]

Pharmacokinetics means how the body absorbs, moves, and removes the study drug over time.^[1]

Metabolism means how the body changes the study drug into other substances called metabolites.^[1]

Healthy participants are people without the disease being studied, used here so researchers can see the drug’s basic behavior in the body.^[1]

Table of contents

• Trial overview
• Study design and phases
• Who can participate
• What is being measured
• How results are judged
• Why this study matters

Trial overview

This article is about one clinical trial of HUMAN FIBROBLASTS for refractory wounds, which are wounds that are hard to heal.^[1] The study is interventional, which means the researchers give a study treatment and then watch what happens.^[1]

The trial is authorised and plans to include 52 people.^[1] It uses topical use, meaning the treatment is applied on the skin or wound area rather than taken by mouth.^[1]

Study design and phases

This is a Phase 1/2 study.^[1] Phase 1 studies usually focus on safety first, while Phase 2 studies look more closely at whether the treatment may help.^[1]

The study has two parts.^[1] In the first part, the team uses an open-label, dose escalation design to test two different doses and find the best dose for the next part.^[1] In the second part, the selected dose is tested further to assess efficacy, which means how well it works, and to confirm safety and tolerability.^[1]

Open-label means the study is not blinded, so the participants and investigators know what is being used.^[1] Dose escalation means the study checks more than one strength in steps before choosing the best one.^[1]

Who can participate

The trial is designed for people with chronic refractory wounds.^[1] The source data do not give more detailed entry rules, such as age limits or other medical requirements.^[1]

Because the study focuses on wounds that do not heal easily, it is meant for patients who have a long-lasting wound problem and need new treatment options.^[1]

What is being measured

The main safety measures include Treatment Emergent Adverse Events, also called TEAEs, which are problems that happen after the product is applied.^[1] The study also checks changes in physical examination findings, vital signs, 12-lead ECG, blood tests, and urine tests.^[1]

Another safety measure is the investigator’s overall tolerability score on a 5-point Likert scale, which is a simple rating scale from very well tolerated to not tolerated at all.^[1]

The efficacy measures focus on wound healing and symptom relief.^[1] These include change in ulcer size, change in wound area in square centimeters, change in the Wound Bed Score, and change in wound pain using a Visual Analogue Scale or VAS, which is a pain rating scale.^[1]

The study also measures the number of responders, meaning people whose ulcer area is reduced by at least 50%, the time to 50% wound reduction, the time to healing if healing happens, and changes in the Wound-QoL-14 questionnaire, which looks at quality of life related to the wound.^[1]

How results are judged

The wound size outcome is scored in six categories, from unchanged to fully healed.^[1] This helps the researchers see not only whether a wound gets smaller, but also whether it closes completely.^[1]

The study also looks at the investigator’s satisfaction with the product’s efficacy using a 5-point Likert scale, which helps show how the treatment performs in real clinical use.^[1] Together, these results are meant to give a full picture of safety, healing progress, pain, and patient impact.^[1]

Why this study matters

People with refractory wounds often need new options because their wounds are slow to improve.^[1] This trial is important because it first tries to find the best dose and then checks whether the chosen dose may help wounds heal better.^[1]

The study is focused on practical outcomes that matter to patients, such as wound size, pain, healing time, and quality of life.^[1] That makes it a patient-centered trial, with both safety and everyday wound improvement in view.^[1]

Table of contents

• Trial overview
• Who can participate
• Study design and phase
• What is being measured
• What the trial is trying to learn
• Key terms explained

Trial overview

The available trial data describe one interventional study of 3-[(3AS,6AR)-5-{5-CHLORO-2-[(1-METHYL-1H-PYRAZOL-4-YL)AMINO]PYRIMIDIN-4-YL}-3A-METHYLHEXAHYDROPYRROLO[3,4-C]PYRROL-2(1H)-YL]-3-OXOPROPANENITRILE in people with prurigo nodularis, a condition with severe itching and skin nodules. The study is authorised and plans to enroll 135 participants.^[1]

The study title says it is a randomized, double-blind, placebo-controlled, and dose-ranging phase 2 trial. In simple words, participants are assigned by chance, neither the participants nor the study team know who gets which treatment, and the trial compares the study drug with a placebo while checking more than one dose.^[1]

Who can participate

The source data say the trial is for adult participants with prurigo nodularis.^[1] No other eligibility details are provided in the trial record, so the available information does not list extra requirements such as past treatments, disease severity, or other health conditions.

• Adults only: The study is not described as open to children or teenagers.^[1]

• Specific condition: Participants must have prurigo nodularis, because that is the condition being studied.^[1]

Study design and phase

This is a phase 2 study, which usually means researchers are looking for early signs that the treatment may help, while still watching safety closely.^[1] The trial is also placebo-controlled, so the study drug is compared with a treatment that looks the same but does not contain the active substance.^[1]

The study is dose-ranging, which means more than one dose is being evaluated. The intervention list mentions placebo and 3-[(3AS,6AR)-5-{5-CHLORO-2-[(1-METHYL-1H-PYRAZOL-4-YL)AMINO]PYRIMIDIN-4-YL}-3A-METHYLHEXAHYDROPYRROLO[3,4-C]PYRROL-2(1H)-YL]-3-OXOPROPANENITRILE given orally at 120 mg.^[1]

What is being measured

The main endpoint is the percent change from baseline in the weekly average Peak pruritus-numeric rate scale (PP NRS) at Week 16.^[1] In patient-friendly language, this means the study is checking how much the worst itching score changes after treatment compared with the starting point.

Because the endpoint focuses on itch, the trial is mainly trying to learn whether the treatment can reduce itching in people with prurigo nodularis.^[1]

What the trial is trying to learn

The brief summary says the study aims to evaluate the treatment efficacy of ICP-332 versus placebo in adult participants with PN.^[1] ICP-332 is the study name used in the trial title for 3-[(3AS,6AR)-5-{5-CHLORO-2-[(1-METHYL-1H-PYRAZOL-4-YL)AMINO]PYRIMIDIN-4-YL}-3A-METHYLHEXAHYDROPYRROLO[3,4-C]PYRROL-2(1H)-YL]-3-OXOPROPANENITRILE.^[1]

From the source data, the key goals are to compare the study drug with placebo, look at different doses, and measure whether itching improves by Week 16.^[1] The record also shows that safety is part of the study title, so safety is being assessed along with efficacy.^[1]

Key terms explained

Randomized means treatment is assigned by chance, which helps make the comparison fair.^[1] Double-blind means neither the participants nor the study team know who is receiving the active treatment or placebo during the study.^[1]

Placebo means a look-alike treatment with no active substance, used to help show whether the study drug works better than no active treatment.^[1] Baseline means the starting measurement before treatment begins.^[1]

Primary outcome means the main result the researchers plan to measure first.^[1] Enrollment means the number of people planned for the study, which here is 135.^[1]

Table of Contents

• Trial overview
• Who can join
• What is being measured
• Trial design and treatment groups
• Trial status and size

Trial overview

The available study of IDOR-1117-2520C is a Phase 2 interventional trial in adults with moderate to severe chronic plaque psoriasis, with or without psoriatic arthritis.^[1]

The trial is authorised and is designed to explore both efficacy and safety, meaning the researchers want to see whether the study treatment may help and whether it can be used safely in this patient group.^[1]

Who can join

The study is for adults with moderate to severe chronic plaque psoriasis.^[1]

People may join whether or not they also have psoriatic arthritis, which is a form of joint inflammation linked to psoriasis.^[1]

What is being measured

The main endpoint, or main result the study wants to measure, is the change from baseline to Week 12 in the Psoriasis Area and Severity Index (PASI) score.^[1]

A PASI score is a way to measure how serious psoriasis is by looking at the affected skin and how severe the patches are.^[1]

Trial design and treatment groups

This is an interventional study, which means researchers assign participants to a study treatment group.^[1]

The trial compares IDOR-1117-2520C with matching placebo, which is a look-alike treatment that does not contain the study drug and helps show whether any change is due to the study treatment.^[1]

The intervention listed for IDOR-1117-2520C is oral, meaning it is taken by mouth in the study setting.^[1]

Trial status and size

The trial status is authorised.^[1]

The planned enrollment is 30 participants, so this is a small trial meant to explore the treatment in a limited group of patients.^[1]

Table of contents

• Trial overview
• Study design and treatment comparison
• Who can participate
• What the trial measures
• Trial status and size

Trial overview

The available trial is a study to investigate the efficacy and safety of HUMAN IGG1 BISPECIFIC MONOCLONAL ANTIBODY AGAINST KALLIKREIN-5 AND KALLIKREIN-7 compared with placebo in adults with moderate to severe atopic dermatitis.^[1]

The study is described as an interventional trial, which means researchers assign a study treatment and then measure the results.^[1]

Study design and treatment comparison

This trial compares TRIV-509 with a placebo, which is a look-alike treatment used for comparison.^[1]

The brief summary says the study is assessing TRIV-509 given by subcutaneous injection for 12 weeks in adults with moderate to severe atopic dermatitis.^[1]

The source also lists TRIV-509 placebo as the comparison treatment in the study.^[1]

Who can participate

The trial is focused on adults with moderate to severe atopic dermatitis.^[1]

No other participant rules are provided in the source data, so the available information only confirms the age group and the condition being studied.^[1]

What the trial measures

The primary outcome is the percentage of participants with improvement of atopic dermatitis at Week 16.^[1]

This means the study will measure how many people improved after treatment, using a specific time point in the study schedule.^[1]

The trial summary also shows that the study aims to assess efficacy and safety, so both benefit and tolerability are part of the research goal.^[1]

Trial status and size

The trial status is Authorised.^[1]

It is a Phase 2 study with planned enrollment of 90 participants.^[1]

Phase 2 trials usually help researchers learn more about whether a treatment may work while continuing to monitor safety, and this study fits that research stage.^[1]

Table of contents

• Trial overview
• Who was studied
• What was tested
• Trial endpoints and outcomes
• Trial status and size
• What these trials mean for patients

Trial overview

The available records describe one clinical study, NCT04500834, for a metal panel patch test that includes ZINC CHLORIDE as one of the allergens being studied.^[1] The study is listed as an interventional study, which means researchers actively test the patch test method in participants.^[1]

Two records are shown for the same trial ID, with different status and enrollment numbers: one is Withdrawn and the other is Authorised.^{[1][2] Both records are Phase 3 studies.[1][2]}

Who was studied

The trials focus on people with allergic contact dermatitis, which is a skin allergy caused by contact with a trigger on the skin.^{[1][2] One record also includes eczema as a condition studied.[1]}

The source data do not give full eligibility rules, so we cannot say exactly who could join beyond the listed conditions.^{[1][2] The intervention list suggests the study involved testing for several metal allergens, including ZINC CHLORIDE.[1][2]}

What was tested

ZINC CHLORIDE appears in the study as Zinc Allergen (zinc chloride 1%) used by cutaneous, or skin, application.^{[1][2] The panel also included other metal allergens such as nickel, copper, tin, manganese, gold, sodium, vanadium, chromium, cobalt, and ammonium-related compounds.[1][2]}

The brief summary says the study aimed to evaluate the diagnostic efficacy and safety of the investigational allergens, as well as the safety and performance of the panel device constituent.^{[1][2] Diagnostic efficacy means how well the test helps find the allergy correctly.[1][2]}

Trial endpoints and outcomes

The main outcome was concordance, which means agreement, between two patch testing methods: a hydrogel investigational allergen method and a petrolatum reference allergen method.^{[1][2] The study used Cohen’s kappa and positive and negative percent agreement to measure that agreement.[1][2]}

These measures help show whether the new testing approach gives results similar to the reference method.^{[1][2] The source data do not list any secondary endpoints beyond the safety and performance goals in the summary.[1][2]}

Trial status and size

One record reports enrollment of 300 participants and the status Withdrawn.^[1] The other record reports enrollment of 395 participants and the status Authorised.^[2]

Because both records use the same NCT number, they appear to be different registry entries or updates for the same study.^{[1][2] The source data do not explain why the status differs.[1][2]}

What these trials mean for patients

For patients, these studies are about improving how doctors identify metal allergies on the skin, not about treating the allergy itself.^{[1][2] ZINC CHLORIDE is being used as one of several patch test allergens in a broader panel, so the focus is on test accuracy and safety.[1][2]}

In simple terms, the researchers want to know whether the patch test results from the study method match the reference method well enough to be trusted.^{[1][2] The trial data point to people with allergic contact dermatitis, and in one record, eczema, as the main groups of interest.[1][2]}

Table of Contents

• What is ZIRCONIUM (89ZR) CREFMIRLIMAB BERDOXAM?
• How does it work?
• What is it used for?
• How is it administered?
• Potential side effects
• Ongoing research

What is ZIRCONIUM (89ZR) CREFMIRLIMAB BERDOXAM?

ZIRCONIUM (89ZR) CREFMIRLIMAB BERDOXAM is an innovative imaging agent used in positron emission tomography (PET) scans. It is also known by several other names, including:

• Zirconium Zr 89 crefmirlimab berdoxam
• 89Zr-Df-IAB22M2C
• 89Zr-desferrioxamine-IAB22M2C
• RO7499775

This compound is not a drug used to treat diseases, but rather a diagnostic tool to help doctors visualize certain cells in the body^[1].

How does it work?

ZIRCONIUM (89ZR) CREFMIRLIMAB BERDOXAM works by targeting and attaching to CD8+ T cells in the body. CD8+ T cells are a type of immune cell that plays a crucial role in fighting cancer and infections. The zirconium-89 component of the compound emits a small amount of radiation that can be detected by a PET scanner, allowing doctors to see where these important immune cells are located in the body^[2].

What is it used for?

This imaging agent is being studied for use in several medical conditions:

1. Cancer: It can help doctors visualize how the immune system is responding to cancer, particularly in patients receiving immunotherapy treatments. This includes:
   • Non-small cell lung cancer
   • Metastatic melanoma (skin cancer that has spread)
   • Other solid tumors
2. Inflammatory diseases:
   • Rheumatoid arthritis (a condition causing joint inflammation)
   • Giant cell arteritis (inflammation of blood vessels, typically in the head)

By showing where CD8+ T cells are concentrated, this imaging technique can help doctors:

• Assess how well cancer treatments are working
• Predict which patients might respond best to certain therapies
• Detect early signs of side effects from immunotherapy
• Monitor inflammation in autoimmune diseases

^[3][4][5]

How is it administered?

ZIRCONIUM (89ZR) CREFMIRLIMAB BERDOXAM is given as an intravenous injection or infusion. This means it is delivered directly into a vein. The dose is typically measured in megabecquerels (MBq), which is a unit used to measure radioactivity. After receiving the injection, patients undergo a PET/CT scan, usually within a few hours to a few days^[1][5].

Potential side effects

As ZIRCONIUM (89ZR) CREFMIRLIMAB BERDOXAM is a diagnostic agent used in very small quantities, severe side effects are rare. However, potential risks may include:

• Allergic reactions to the compound
• Mild discomfort at the injection site
• Exposure to a small amount of radiation (less than many standard medical imaging procedures)

Patients should inform their healthcare providers of any unusual symptoms or concerns after receiving this imaging agent^[5].

Ongoing research

Several clinical trials are currently underway to further investigate the uses of ZIRCONIUM (89ZR) CREFMIRLIMAB BERDOXAM:

• A study comparing it to another imaging agent in non-small cell lung cancer patients receiving immunotherapy^[1]
• Research on its ability to detect early signs of side effects in melanoma patients receiving immune checkpoint inhibitor therapy^[4]
• Investigations into its use for imaging inflammation in rheumatoid arthritis and giant cell arteritis^[3]
• A study examining its effectiveness in predicting treatment response in various solid tumors^[5]

These studies aim to improve our understanding of how this imaging technique can be used to enhance patient care and treatment decisions.

Table of Contents

• What is [18F]FAPI-74?
• How it Works
• Conditions Being Studied
• How [18F]FAPI-74 is Administered
• Potential Benefits
• Ongoing Research
• Who Can Participate in Studies?
• Conclusion

What is [18F]FAPI-74?

[18F]FAPI-74 is an innovative diagnostic tool currently being studied for its potential in detecting various types of cancer and lung fibrosis^[1][2][3][4]. It is a type of radioactive tracer used in a special imaging technique called PET/CT (Positron Emission Tomography/Computed Tomography). This substance is not yet approved for widespread clinical use and is being evaluated in research studies to determine its effectiveness.

How it Works

[18F]FAPI-74 works by targeting a specific protein called Fibroblast Activation Protein (FAP). This protein is often found in higher amounts in cancerous tissues and areas of inflammation or fibrosis (scarring). When injected into the body, [18F]FAPI-74 attaches to these FAP proteins, allowing doctors to see potential problem areas more clearly on PET/CT scans^[3].

Conditions Being Studied

Research is currently focusing on the use of [18F]FAPI-74 PET/CT for several conditions:

• Pancreatic cancer: To detect the spread of cancer to nearby lymph nodes and distant parts of the body^[1].
• Colon cancer: To identify cancer that has spread to lymph nodes or other areas^[2].
• Prostate cancer: To evaluate how the cancer has spread in patients with advanced disease^[3].
• Lung fibrosis in connective tissue diseases: To detect early signs of lung scarring in patients with certain autoimmune conditions^[4].

How [18F]FAPI-74 is Administered

[18F]FAPI-74 is given as a solution for injection, typically through an intravenous (IV) route. This means it’s injected directly into a vein, usually in your arm. The dose can vary depending on the specific study, but ranges from about 250 to 400 MBq (megabecquerels, a unit of radioactivity)^[1][2][3][4].

Potential Benefits

The potential benefits of [18F]FAPI-74 PET/CT include:

• More accurate detection of cancer spread, which could help in planning treatments^[1][2].
• Earlier detection of lung fibrosis in patients with certain autoimmune diseases, potentially allowing for earlier treatment^[4].
• Improved understanding of how different cancers behave and spread in the body^[3].

Ongoing Research

Several clinical trials are currently underway to evaluate the effectiveness of [18F]FAPI-74:

• A study comparing [18F]FAPI-74 to other imaging techniques for detecting prostate cancer spread^[3].
• Research on using [18F]FAPI-74 to predict which patients with connective tissue diseases might develop progressive lung fibrosis^[4].
• Studies assessing how well [18F]FAPI-74 can detect lymph node involvement in pancreatic and colon cancers^[1][2].

Who Can Participate in Studies?

Eligibility for [18F]FAPI-74 studies varies depending on the specific research, but generally includes:

• Adults aged 18-85 years old
• Patients with confirmed or suspected cancer (depending on the study)
• Individuals with certain autoimmune diseases (for the lung fibrosis study)
• Generally good overall health (usually measured by a WHO performance score of 0-2, which indicates the patient’s ability to care for themselves and carry out daily activities)

Patients who are pregnant, breastfeeding, or have certain medical conditions that prevent whole-body PET/CT imaging are typically not eligible for these studies^[1][2][3][4].

Conclusion

[18F]FAPI-74 is a promising new tool in the field of medical imaging. While it’s still in the research phase, early studies suggest it could significantly improve our ability to detect and monitor certain cancers and lung conditions. As research continues, we may learn more about its potential uses and benefits for patients.

Table of Contents

• Trial overview
• Study design and phase
• Who is being studied
• What the trial measures
• Placebo and blinding
• Trial summary

Trial overview

The provided trial data include one interventional study of VALACICLOVIR HYDROCHLORIDE for people with HSV-2 meningitis.^[1] The study is titled “Aciclovir for HSV-2 MENingitis: A double-blinded randomised controlled trial (AMEN),” and it is authorised.^[1] Its brief summary says the researchers want to see whether active treatment with (val)acyclovir is better than placebo for viral meningitis.^[1]

Study design and phase

This is a Phase 3 trial, which means it is a later-stage study meant to test how well the treatment works in a patient group.^[1] It is a randomised controlled trial, so participants are assigned by chance to different study groups.^[1] The study is also double-blinded, which means the patient and the study team do not know who receives active treatment or placebo.^[1]

Who is being studied

The target condition in this trial is HSV-2 meningitis.^[1] The source data do not list all inclusion or exclusion rules, but the study is clearly aimed at patients with this diagnosis.^[1] The planned enrollment is 150 participants, which gives an idea of the study size.^[1]

What the trial measures

The primary outcome is the proportion of patients with a Total Morbidity Score (TMS) greater than 6 at 7 days after randomisation.^[1] In simple terms, the researchers are checking how many patients still have a higher illness burden one week after the study starts.^[1] This endpoint helps show whether the treatment leads to better short-term recovery compared with placebo.^[1]

Placebo and blinding

The interventions listed include active intravenous aciclovir, oral VALACICLOVIR HYDROCHLORIDE, and matching placebo products.^[1] The placebo tablets and placebo intravenous treatment are made to look like the active products, which helps keep the comparison fair.^[1] Because the study is double-blinded, the results are less likely to be influenced by expectations from patients or researchers.^[1]

Trial summary

In the available data, VALACICLOVIR HYDROCHLORIDE is being studied in one Phase 3 trial for HSV-2 meningitis.^[1] The study asks whether active treatment is superior to placebo and uses a short-term clinical score as the main outcome.^[1] The trial is authorised, randomised, and double-blinded, with 150 planned participants.^[1]

Table of Contents

• Trial overview
• Who the studies are for
• What VANADIUM OXIDE SULFATE is being studied for
• Main outcomes and endpoints
• Study phase and status
• Trial summary

Trial overview

The available trial records describe a study called Metal Panel Patch Test and identify VANADIUM OXIDE SULFATE as one of the patch test allergens being studied.^[1] The study is listed as an interventional trial, which means researchers actively test a patch method rather than only observing people.^[1]

The records show the same study ID, NCT04500834, with two status entries: Withdrawn and Authorised.^{[1][2] Both records describe a Phase 3 study focused on patch testing and metal allergens.[1][2]}

Who the studies are for

The target conditions are allergic contact dermatitis and, in one record, eczema.^{[1][2] These are skin conditions, and allergic contact dermatitis happens when the skin reacts to something it touches.[1][2]}

The trial data do not list detailed age limits, sex limits, or other participation rules. Based on the source, the main population is people being tested for metal-related skin allergy.^[1][2]

What VANADIUM OXIDE SULFATE is being studied for

In these records, VANADIUM OXIDE SULFATE appears as Vanadium Allergen at 1.3% for cutaneous use, meaning it is placed on the skin as part of patch testing.^{[1][2] It is studied alongside other metal allergens such as nickel, copper, tin, manganese, zinc, gold, sodium, ammonium, cobalt, and chromium.[1][2]}

The trial is not presented as a treatment study. Instead, it is a diagnostic study, meaning it is trying to see how well the test identifies allergy and how well two test methods perform.^[1][2]

Main outcomes and endpoints

The primary outcome is concordance, which means agreement, between the hydrogel investigational allergen method and the petrolatum reference allergen method.^{[1][2] The study measures this using Cohen’s kappa, a statistic that checks agreement beyond chance, and by positive and negative percent agreement.[1][2]}

The brief summary says the objective is to evaluate the diagnostic efficacy and safety of the investigational allergens and the overall safety and performance of the panel device constituent.^{[1][2] In simple terms, the researchers want to know whether the test works well and whether it can be used safely in patch testing.[1][1]}

Study phase and status

Both records list the study as Phase 3.^{[1][2] Phase 3 studies are later-stage studies that usually focus on how well a method works in a larger group of people.[1][2]}

One record is marked Withdrawn with planned enrollment of 300 people, while the other is marked Authorised with planned enrollment of 395 people.^{[1][2] The source does not explain why the status differs, so the records should be read as separate registry entries for the same study ID.[1][2]}

Trial summary

Overall, the clinical trial data for VANADIUM OXIDE SULFATE focus on patch testing in people with allergic contact dermatitis, and in one record, eczema.^{[1][2] The study compares two ways of doing patch tests and checks how closely the results match.[1][2] The main endpoint is agreement between methods, not symptom relief or treatment of disease.[1][2]}

The records provide a clear research focus: diagnostic performance, safety, and practical use of the allergen panel in skin testing.^[1][2]

Table of Contents

• What is VIBOZILIMOD?
• What Conditions Does VIBOZILIMOD Treat?
• How Does VIBOZILIMOD Work?
• Clinical Trials and Effectiveness
• Dosage and Administration
• Who is Eligible for VIBOZILIMOD Treatment?
• Potential Side Effects

What is VIBOZILIMOD?

VIBOZILIMOD, also known as SCD-044, is a new medication being developed to treat certain skin conditions^[1][2]. It is currently undergoing clinical trials to evaluate its safety and effectiveness. VIBOZILIMOD is classified as a selective immunosuppressive agent, which means it works by modulating the immune system to reduce inflammation and other symptoms associated with certain skin diseases.

What Conditions Does VIBOZILIMOD Treat?

VIBOZILIMOD is being studied for the treatment of two main skin conditions:

1. Moderate to severe plaque psoriasis: This is a chronic autoimmune condition that causes rapid buildup of skin cells, resulting in scaly, itchy, and inflamed patches on the skin^[1].
2. Moderate to severe atopic dermatitis: Also known as eczema, this is a chronic inflammatory skin condition characterized by dry, itchy, and inflamed skin^[2].

How Does VIBOZILIMOD Work?

While the exact mechanism of action is not fully described in the provided information, VIBOZILIMOD belongs to a class of drugs called selective immunosuppressive agents^[1][2]. These medications work by targeting specific components of the immune system to reduce inflammation and other symptoms associated with autoimmune skin conditions. By modulating the immune response, VIBOZILIMOD aims to alleviate the symptoms and improve the overall condition of patients with psoriasis and atopic dermatitis.

Clinical Trials and Effectiveness

VIBOZILIMOD is currently being evaluated in Phase IIb clinical trials for both plaque psoriasis and atopic dermatitis^[1][2]. These trials are designed to assess the drug’s efficacy and safety. The main objectives of these studies include:

• For plaque psoriasis: To determine the proportion of patients who achieve at least a 75% improvement in the Psoriasis Area and Severity Index (PASI) score after 16 weeks of treatment^[1]. This is known as PASI75 and is a standard measure of effectiveness in psoriasis treatments.
• For atopic dermatitis: To evaluate the proportion of patients who achieve at least a 75% improvement in the Eczema Area and Severity Index (EASI) score after 16 weeks of treatment^[2]. This is referred to as EASI75 and is a common measure of effectiveness in atopic dermatitis treatments.

These trials will help determine how well VIBOZILIMOD works compared to a placebo and at what doses it is most effective.

Dosage and Administration

VIBOZILIMOD is being tested in tablet form and is taken orally. The clinical trials are evaluating different dosage strengths, including:

• 0.1 mg tablets
• 0.3 mg tablets
• 0.6 mg tablets
• 1.0 mg tablets

The exact dosing regimen and duration of treatment may vary depending on the condition being treated and the results of the ongoing clinical trials^[1][2].

Who is Eligible for VIBOZILIMOD Treatment?

As VIBOZILIMOD is still in clinical trials, eligibility for treatment is currently limited to study participants. The general criteria for participation in these trials include:

• Adults aged 18 years or older
• Diagnosed with moderate to severe plaque psoriasis or atopic dermatitis for at least 6 months or 1 year, respectively
• For psoriasis: at least 10% body surface area affected, a PASI score of 12 or higher, and an Investigator’s Global Assessment (IGA) score of at least 3 (indicating moderate disease)^[1]
• For atopic dermatitis: meeting the Eichenfield revised criteria of Hanifin and Rajka for diagnosis^[2]
• Not pregnant or breastfeeding
• No history of certain medical conditions, such as uveitis (inflammation of the middle layer of the eye)

Potential Side Effects

As VIBOZILIMOD is still in clinical trials, the full range of potential side effects is not yet known. The ongoing studies will help identify any adverse reactions associated with the medication. It’s important to note that all medications can have side effects, and the benefits and risks should be carefully considered under the guidance of a healthcare professional.

Patients participating in the clinical trials will be closely monitored for any adverse effects throughout the study period^[1][2].